Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Ligand Pharm (LGND)

Ligand Pharm (LGND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,413,662
  • Shares Outstanding, K 16,677
  • Annual Sales, $ 186,420 K
  • Annual Income, $ -2,990 K
  • 60-Month Beta 1.14
  • Price/Sales 12.08
  • Price/Cash Flow 20.96
  • Price/Book 2.93
Trade LGND with:

Options Overview

Details
  • Implied Volatility 50.01%
  • Historical Volatility 65.45%
  • IV Percentile 15%
  • IV Rank 6.32%
  • IV High 157.34% on 01/27/21
  • IV Low 42.77% on 09/17/21
  • Put/Call Vol Ratio 0.92
  • Today's Volume 23
  • Volume Avg (30-Day) 132
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,121
  • Open Int (30-Day) 779

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 0.61
  • Number of Estimates 1
  • High Estimate 0.61
  • Low Estimate 0.61
  • Prior Year 0.71
  • Growth Rate Est. (year over year) -14.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
105.02 +33.45%
on 08/23/21
145.36 -3.58%
on 09/17/21
+36.05 (+34.63%)
since 08/20/21
3-Month
102.01 +37.39%
on 08/19/21
145.36 -3.58%
on 09/17/21
+13.54 (+10.69%)
since 06/18/21
52-Week
78.26 +79.08%
on 10/30/20
219.75 -36.22%
on 02/10/21
+48.07 (+52.20%)
since 09/18/20

Most Recent Stories

More News
Performance Food Group & Digital Turbine Set to Join S&P MidCap 400; TreeHouse Foods & Ligand Pharmaceuticals to Join S&P SmallCap 600

/PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600:

APPS : 63.62 (-4.85%)
CORE : 45.65 (-0.76%)
LGND : 138.59 (-4.24%)
CBB : 15.48 (-0.06%)
PFGC : 44.39 (-2.03%)
THS : 38.23 (-0.91%)
SPGI : 444.88 (-0.34%)
Ligand's Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin's Lymphoma

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Gloria Biosciences (GloriaBio) has received approval from China's National Medical Products Administration (NMPA) for...

LGND : 138.59 (-4.24%)
Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

--Sparsentan has been generally well-tolerated and consistent with the previously observed safety profile to date

LGND : 138.59 (-4.24%)
TVTX : 22.36 (-0.67%)
New Strong Sell Stocks for August 5th

AZRX, GHL, HEES, LGND, and POLY have been added to the Zacks Rank #5 (Strong Sell) List on August 5, 2021.

LGND : 138.59 (-4.24%)
GHL : 13.47 (-3.09%)
HEES : 32.32 (-5.28%)
AZRX : 3.53 (-5.87%)
POLY : 27.50 (-4.25%)
Ligand (LGND) Q2 Earnings & Sales Beat, 2021 Guidance Cut

Ligand (LGND) reports encouraging second-quarter 2021 numbers by beating estimates on both counts.

MRK : 72.40 (+1.00%)
AMGN : 217.69 (-0.77%)
GILD : 71.37 (-0.34%)
LGND : 138.59 (-4.24%)
Ligand Pharmaceuticals (LGND) Q2 Earnings and Revenues Top Estimates

Ligand (LGND) delivered earnings and revenue surprises of 12.41% and 15.49%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

LGND : 138.59 (-4.24%)
Ligand: Q2 Earnings Snapshot

SAN DIEGO (AP) _ Ligand Pharmaceuticals Inc. (LGND) on Thursday reported second-quarter net income of $30.7 million.

LGND : 138.59 (-4.24%)
Landing AI's LandingLens™ visual inspection software platform selected by Ligand Pharmaceuticals to further empower the OmniAb® and xPloration™ antibody discovery platforms

/PRNewswire/ -- Landing AI announced today a software licensing agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to incorporate LandingLens into Ligand's OmniAb and xPloration antibody...

LGND : 138.59 (-4.24%)
Ligand Partner Jazz Pharmaceuticals Launches RYLAZE(TM) (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458

--Rylaze for the treatment of ALL or LBL utilizes Ligand's Pelican Expression Technology(TM) Platform

LGND : 138.59 (-4.24%)
JAZZ : 131.24 (-1.49%)
Ligand's Partner Merck Receives FDA Approval for VAXNEUVANCE(TM) for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Merck has received approval from the U.S. Food and Drug Administration (FDA) for VAXNEUVANCE(TM), also known as V114, for the...

LGND : 138.59 (-4.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases....

See More

Key Turning Points

3rd Resistance Point 159.27
2nd Resistance Point 152.32
1st Resistance Point 148.52
Last Price 138.59
1st Support Level 137.77
2nd Support Level 130.82
3rd Support Level 127.02

See More

52-Week High 219.75
Fibonacci 61.8% 165.70
Fibonacci 50% 149.01
Last Price 138.59
Fibonacci 38.2% 132.31
52-Week Low 78.26

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar